12 completed, 6 recruiting, 5 terminated, 1 active not recruiting. 27 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 27 | Completed 12, Recruiting 6, Terminated 5, Active not recruiting 1, Not yet recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 2, Recruiting 1, Terminated 1 |
Follow Adrenal Cortex Diseases: new trials by email Literature Review of Adrenal Cortex Diseases trials Research Report on Adrenal Cortex Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy Carfilzomib - Colorectal Neoplasms, Neoplasms | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 20 | 2026-11-08 | 2026-11-03 |
| Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical Carcinoma Surgical resection, Preoperative RT - Adrenocortical Carcinoma (ACC), Recurrent Adrenocortical Carcinoma (ACC) | Phase 1 | Recruiting | National Cancer Institute (NCI) | 32 | 2026-11-08 | 2026-11-03 |
| A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer DS9051b - Advanced or Metastatic Adrenocortical Carcinoma, Metastatic Castration-resistant Prostate Cancer | Phase 1 | Recruiting | Daiichi Sankyo | 40 | 2025-11-04 | 2026-05-22 |
| Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Biopsy, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Metastatic Melanoma | Phase 1 | Recruiting | Anusha Kalbasi | 18 | 2025-10-07 | 2026-03-17 |
| Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). Olaparib; 177Lu-DOTATATE - Solid Tumor Cancer, Medulloblastoma | Phase 1 / Phase 2 | Recruiting | Fundación de investigación HM | 25 | 2024-09-20 | 2026-06-04 |
| A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors ADCT-701 - Neuroendocrine Carcinomas, Neuroendocrine Tumors | Phase 1 | Recruiting | National Cancer Institute (NCI) | 70 | 2024-06-17 | 2026-11-02 |
| Phase 1 Study of 68Ga-R8760 68Ga-R8760 injection at pre-defined dose levels, 68Ga-R8760 injection - Adrenocortical Carcinoma | Phase 1 | Terminated | Radionetics Oncology | 11 | 2023-09-11 | 2024-12-09 |
| B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) Fludarabine, Cyclophosphamide, MESNA - Pediatric Solid Tumor, Osteosarcoma | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 48 | 2022-07-06 | 2026-05-19 |
| Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol) Relacorilant, Pembrolizumab - Adrenocortical Carcinoma | Phase 1 | Completed | Corcept Therapeutics | 15 | 2020-09-30 | 2024-02-23 |
| A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma EO2401, Nivolumab - Adrenocortical Carcinoma, Pheochromocytoma | Phase 1 / Phase 2 | Terminated | Enterome | 70 | 2020-07-23 | 2026-01-30 |
| A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC) E7386 - Solid Neoplasms, Colorectal Neoplasms | Phase 1 | Active not recruiting | Eisai Co., Ltd. | 70 | 2019-03-05 | 2026-02-27 |
| A Phase 1 Study of [225Ac]-FPI-1434 Injection [111In]-FPI-1547 Injection, [225Ac]-FPI-1434 Injection multi-dose, FPI-1175 Infusion - Advanced Solid Tumours, Endometrial Cancer | Phase 1 | Terminated | Fusion Pharmaceuticals Inc. | 78 | 2019-01-17 | 2026-01-07 |
| Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Capecitabine, Temozolomide, Veliparib - Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma | Phase 1 | Withdrawn | Vanderbilt-Ingram Cancer Center | 2017-12-01 | 2017-09-28 | |
| A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR) ABBV-176 - Advanced Solid Tumors Cancer | Phase 1 | Terminated | AbbVie | 19 | 2017-07-03 | 2018-11-29 |
| A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 IPI-549 (eganelisib), Nivolumab - Advanced Solid Tumors (Part A/B/C/D), Non-small Cell Lung Cancer (Part E) | Phase 1 | Unknown | Infinity Pharmaceuticals, Inc. | 219 | 2015-12-01 | 2022-04-04 |
| Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma ATR-101 - Adrenocortical Carcinoma, Adrenal Cancer | Phase 1 | Completed | Millendo Therapeutics, Inc. | 63 | 2013-08-13 | 2017-11-06 |
| Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) Avelumab - Solid Tumors | Phase 1 | Completed | EMD Serono Research & Development Institute, Inc. | 1756 | 2013-01-31 | 2021-12-20 |
| Possible New Therapy for Advanced Cancer IL-13-PE - Adrenocortical Carcinoma | Phase 1 | Terminated | INSYS Therapeutics Inc | 9 | 2012-12-01 | 2015-04-27 |
| A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients TKM-080301 - Cancer, Neuroendocrine Tumors | Phase 1 / Phase 2 | Completed | Arbutus Biopharma Corporation | 68 | 2010-12-01 | 2019-01-16 |
| Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Seneca Valley virus-001, cyclophosphamide, laboratory biomarker analysis - Adrenocortical Carcinoma, Gastrointestinal Carcinoid Tumor | Phase 1 | Completed | Children's Oncology Group | 22 | 2009-09-01 | 2014-01-30 |
Showing 20 of 27. Sign in to see all of them.
Adrenocortical Carcinoma (23) · Breast Neoplasms (8) · Neoplasms (7) · Adrenal Cortex Neoplasms (5) · Carcinoma, Hepatocellular (5) · Carcinoma, Non-Small-Cell Lung (5) · Carcinoma, Renal Cell (5) · Colorectal Neoplasms (5) · Melanoma (5) · Neuroblastoma (5) · Neuroendocrine Tumors (5) · Pheochromocytoma (5) · Squamous Cell Carcinoma of Head and Neck (5) · Adrenal Gland Neoplasms (4) · Colonic Neoplasms (4)
Adrenal Gland Diseases (26) · Endocrine Gland Neoplasms (26) · Endocrine System Diseases (26) · Neoplasms by Histologic Type (26) · Neoplasms by Site (26) · Neoplasms, Glandular and Epithelial (26) · Carcinoma (24) · Adenocarcinoma (23) · Adrenal Gland Neoplasms (22) · Adrenal Cortex Neoplasms (21) · Neoplasms (19) · Neoplasms, Nerve Tissue (15) · Neuroectodermal Tumors (15) · Neoplasms, Germ Cell and Embryonal (14)
Cyclophosphamide (3) · Nivolumab (2) · Trastuzumab (2) · fludarabine phosphate (2) · Adrenocorticotropic Hormone (1) · Biopsy (1) · Capecitabine (1) · Cisplatin (1) · Cosyntropin (1) · Cytoreduction Surgical Procedures (1) · Doxorubicin (1) · E-7386 (1) · Fluorodeoxyglucose F18 (1) · IPI-549 (1) · Interleukin-12 (1)
National Cancer Institute (NCI) (5) · Mayo Clinic (2) · AbbVie (1) · Anusha Kalbasi (1) · Arbutus Biopharma Corporation (1) · Children's Oncology Group (1) · Corcept Therapeutics (1) · Daiichi Sankyo (1) · EMD Serono Research & Development Institute, Inc. (1) · Eisai Co., Ltd. (1) · Enterome (1) · Fundación de investigación HM (1) · Fusion Pharmaceuticals Inc. (1) · INSYS Therapeutics Inc (1) · Infinity Pharmaceuticals, Inc. (1)
United States (23) · Germany (4) · France (3) · Spain (3) · Australia (2) · Denmark (2) · United Kingdom (2) · Belgium (1) · Canada (1) · Czechia (1) · Italy (1) · Japan (1) · Netherlands (1) · Poland (1) · South Korea (1)
Alex A. Adjei, MD, PhD (1) · Allison Betof Warner, MD, PhD (1) · Andrea Hayes-Jordan, MD (1) · Andreas G Moraitis, MD (1) · Anthony W. Tolcher, MD (1) · Antoni Ribas, MD, PhD (1) · Chris DeRenzo, MD (1) · Christoph Reiners, MD (1) · Electron Kebebew, M.D. (1) · Feng Chi, MD (1) · Jaydira Del Rivero, M.D. (1) · Jean-Michel Paillarse (1) · Jonathan M Hernandez, M.D. (1) · Jordan Berlin, M.D. (1)
PMID 26666256, PMID 28239472, PMID 29217288, PMID 30348224, PMID 30605211, PMID 30651126, PMID 30676622, PMID 30717797, PMID 31553054, PMID 31639039, PMID 31651359, PMID 31984451, PMID 32524319, PMID 32849281, PMID 32907924, PMID 33219092, PMID 34663640, PMID 36383907, PMID 36457575, PMID 36821354, PMID 37310790, PMID 39214650, PMID 39416174, PMID 40595495
2016 (1), 2025 (1), P30CA015083 (1), U01CA069912 (1), U01CA076576 (1)